Illegal weight-loss medicines are facing increased scrutiny as pharmaceutical manufacturers demand stronger law enforcement and regulators prepare tighter rules governing compounded obesity treatments. The Pharmaceutical Task Group (PTG) has called for prosecutions against individuals and businesses selling unregistered medicines. Meanwhile, the South African Health Products Regulatory Authority (SAHPRA) and South African Pharmacy Council are developing updated compounding standards. The interventions…
Tag: Pharmaceutical Regulation
-
Medicine Safety Under Scrutiny after iDexis Case
Recent court proceedings involving Pretoria-based compounding pharmacy iDexis have placed semaglutide medicine safety in the spotlight. The dispute has sparked debate about access to medicines, intellectual property rights and the regulatory powers of the South African Health Products Regulatory Authority (SAHPRA). It has also drawn attention to rising demand for medicines containing semaglutide. This is the active ingredient in registered…
-
iDexis Semaglutide Ban Ordered By High Court
The High Court has temporarily stopped pharmacy group iDexis from manufacturing, supplying and marketing weight-loss medicines containing semaglutide. The iDexis semaglutide ban follows an application by Danish pharmaceutical company Novo Nordisk. The company manufactures Ozempic and Wegovy. Semaglutide is the active ingredient in both medicines. Ozempic is registered as a treatment for diabetes. Wegovy is approved for weight management. The…
-
Compounded GLP-1 Injections Spark Regulatory Battle
South African pharmaceutical firm iDexis is fighting back against local healthcare regulators over its Compounded GLP-1 Weight-Loss Injections. The company strongly defends its product safety amid serious compliance allegations. The dispute follows a joint statement by the South African Health Products Regulatory Authority (SAHPRA) and the South African Pharmacy Council (SAPC). The regulators ordered an immediate recall of the company’s…
-
Surge in Illicit Medicines Threatens Public Health
South Africa is at a critical crossroads in its fight against a rising tide of illicit, substandard, and falsified medicines. These pose a severe threat to public health. The influx is particularly alarming in relation to GLP-1 agonists, the popular class of medicines developed to treat type 2 diabetes and obesity. In response to this escalating crisis, the South African…
-
Substandard Cancer Drugs in Africa Are A Serious Concern
A groundbreaking investigation across four African nations has uncovered a disturbing truth: a significant portion of cancer medications are substandard or counterfeit. This leaves vulnerable patients with treatments that may be ineffective or even harmful. The study, published in The Lancet Global Health, sheds light on a critical and previously unmeasured gap in pharmaceutical regulation on the continent. It highlights…